Xirouchakis E, Kranidioti H, Hadziyanni E, Kourikou A, Reppas C, Vertzoni M
BMC Gastroenterol. 2024; 24(1):420.
PMID: 39574005
PMC: 11580216.
DOI: 10.1186/s12876-024-03483-6.
Burra P, Zanetto A, Schnabl B, Reiberger T, Montano-Loza A, Asselta R
Nat Rev Gastroenterol Hepatol. 2024; 21(12):869-884.
PMID: 39237606
DOI: 10.1038/s41575-024-00974-5.
Malandris K, Paschos P, Katsoula A, Manolopoulos A, Andreadis P, Sarigianni M
Ann Gastroenterol. 2019; 32(3):287-297.
PMID: 31040627
PMC: 6479656.
DOI: 10.20524/aog.2019.0368.
Zacharias A, Jeyaraj R, Hobolth L, Bendtsen F, Gluud L, Morgan M
Cochrane Database Syst Rev. 2018; 10:CD011510.
PMID: 30372514
PMC: 6517039.
DOI: 10.1002/14651858.CD011510.pub2.
Abraldes J, Trebicka J, Chalasani N, DAmico G, Rockey D, Shah V
Hepatology. 2018; 69(3):1287-1299.
PMID: 30318607
PMC: 11090176.
DOI: 10.1002/hep.30314.
Rifaximin and Propranolol Combination Therapy Is More Effective than Propranolol Monotherapy for the Reduction of Portal Pressure: An Open Randomized Controlled Pilot Study.
Lim Y, Kim M, Jang Y, Baik S, Kwon S
Gut Liver. 2017; 11(5):702-710.
PMID: 28651304
PMC: 5593333.
DOI: 10.5009/gnl16478.
Pediatric gastrointestinal bleeding: Perspectives from the Italian Society of Pediatric Gastroenterology.
Romano C, Oliva S, Martellossi S, Miele E, Arrigo S, Graziani M
World J Gastroenterol. 2017; 23(8):1328-1337.
PMID: 28293079
PMC: 5330817.
DOI: 10.3748/wjg.v23.i8.1328.
Non-selective β-blockers in advanced cirrhosis: a critical review of the effects on overall survival and renal function.
Blasco-Algora S, Masegosa-Ataz J, Alonso S, Gutierrez M, Fernandez-Rodriguez C
BMJ Open Gastroenterol. 2017; 3(1):e000104.
PMID: 28074149
PMC: 5174812.
DOI: 10.1136/bmjgast-2016-000104.
Rethinking the role of non-selective beta blockers in patients with cirrhosis and portal hypertension.
Ferrarese A, Zanetto A, Germani G, Burra P, Senzolo M
World J Hepatol. 2016; 8(24):1012-8.
PMID: 27648153
PMC: 5002497.
DOI: 10.4254/wjh.v8.i24.1012.
Cirrhosis and portal hypertension: The importance of risk stratification, the role of hepatic venous pressure gradient measurement.
La Mura V, Nicolini A, Tosetti G, Primignani M
World J Hepatol. 2015; 7(4):688-95.
PMID: 25866605
PMC: 4388996.
DOI: 10.4254/wjh.v7.i4.688.
Use of non-selective beta blockers in cirrhosis: the evidence we need before closing (or not) the window.
La Mura V, Tosetti G, Primignani M, Salerno F
World J Gastroenterol. 2015; 21(8):2265-8.
PMID: 25741132
PMC: 4342901.
DOI: 10.3748/wjg.v21.i8.2265.
Prevention of portal hypertension: from variceal development to clinical decompensation.
Vorobioff J, Groszmann R
Hepatology. 2014; 61(1):375-81.
PMID: 24913395
PMC: 4545530.
DOI: 10.1002/hep.27249.
Beta-blockers in liver cirrhosis.
Giannelli V, Lattanzi B, Thalheimer U, Merli M
Ann Gastroenterol. 2014; 27(1):20-26.
PMID: 24714633
PMC: 3959530.
Management of varices in patients with cirrhosis.
OBrien J, Triantos C, Burroughs A
Nat Rev Gastroenterol Hepatol. 2013; 10(7):402-12.
PMID: 23545523
DOI: 10.1038/nrgastro.2013.51.
Is there any vindication for low dose nonselective β-blocker medication in patients with liver cirrhosis?.
Kim T, Kim H, Chon C, Won H, Park J, Park D
Clin Mol Hepatol. 2012; 18(2):203-12.
PMID: 22893871
PMC: 3415875.
DOI: 10.3350/cmh.2012.18.2.203.
Primary prophylaxis of variceal bleeding.
Baenas M, Thalheimer U, Germani G, Burroughs A
Gastroenterol Hepatol (N Y). 2012; 7(8):560-2.
PMID: 22298996
PMC: 3264944.
Reversible decrease of portal venous flow in cirrhotic patients: a positive side effect of sorafenib.
Coriat R, Gouya H, Mir O, Ropert S, Vignaux O, Chaussade S
PLoS One. 2011; 6(2):e16978.
PMID: 21340026
PMC: 3038868.
DOI: 10.1371/journal.pone.0016978.
Pharmacological effects are model specific in animal models of portal hypertension.
Bendtsen F, Moller S
Hepatol Int. 2009; 2(4):397-8.
PMID: 19669314
PMC: 2716897.
DOI: 10.1007/s12072-008-9097-7.
Variceal bleeding : pharmacological treatment and prophylactic strategies.
Villanueva C, Balanzo J
Drugs. 2008; 68(16):2303-24.
PMID: 18973395
DOI: 10.2165/0003495-200868160-00004.
